Non-Small Cell Lung Cancer
Conditions
Keywords
NSCLC;patients and physicians;survey;EGFR-TKI;patient preference;physician preference
Brief summary
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
Detailed description
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach. The study will collect data from participants via the questionnaire developed by the research team. This study will be conducted in two stages. Stage 1 is the study design phase (i.e., qualitative stage and questionnaire development), which includes the development of the questionnaire, identification of key attributes and levels for the Discrete Choice Experiment (DCE), creation of hypothetical patient profiles to explore high-risk factors in physician decision-making beyond the DCE, as well as questionnaire programming, internal review, pilot testing, revisions, and finalization. Stage 2 involves the implementation of the quantitative survey using the finalized questionnaire and the subsequent data analysis to generate insights into treatment preferences.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
The following inclusion criteria must be met in order to be enrolled in the stage 1: Patient: * Provide informed consent * 18 years or older * Diagnosed with stage IV NSCLC * Currently receiving or previously received 1L EGFR-TKI treatment * Without communication barrier * Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter Physician: * Provide informed consent * Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals * Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month * Holding the title of associate chief physician or higher The following inclusion criteria must be met in order to be enrolled in the stage 2: Patient: * Provide informed consent * 18 years or older * Diagnosed with stage IV NSCLC * Currently receiving or previously received 1L EGFR-TKI treatment * Without communication barrier * Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter Physician: * Provide informed consent * Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals * Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month * Holding the title of attending physician or higher
Exclusion criteria
Not applicable.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Preferences weights for each attribute level evaluated in the DCE | Day of interview/survey completion(Day1) | Preference weights will be estimated for each attribute level included in the DCE where a more positive preference weight indicates a stronger preference for the attribute level. The preference weights allow for comparison for relative preference for levels within the same attribute. |
| Relative attribute importance (RAI) | Day of interview/survey completion(Day1) | The importance measure will be used to evaluate the preferences among treatment attributes. This measure will be calculated by using the difference of utility scores between the most and least preferred levels within an attribute. Then, this measure will divide by the summation of the difference of all tested attributes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum acceptable risks (MAR) and minimum acceptable benefit (MAB) | Day of interview/survey completion(Day1) | This measure will be used to evaluate the trade-offs participants are willing to make between an improvement in a pre-defined attribute related to efficiency (such as PFS) compared to a worsening in each AE relevant attribute (such as rash). * MAR quantifies the average maximum level of risk factors (e.g., incidence of rash, incidence of diarrhea, etc.) that participants are willing to tolerate in exchange for a specified improvement in clinical outcomes. * MAB represents the minimum level of benefit required to justify an increase in risk. It is derived from the marginal rate of substitution (MRS) between risk and benefit attributes, calculated using the estimated preference weights from the DCE model. |
| RAI, MAR, and MAB by patient and physician characteristics subgroups | Day of interview/survey completion(Day1) | * RAI quantifies the relative weight participants place on each attribute (e.g., efficacy vs. side effects) in their decision-making. * MAR and MAB will be estimated separately for subgroups defined by patient (e.g., age, gender, with/without central nervous system \[CNS\] metastasis) and physician (e.g., title, years of experience) characteristics. |
| Odds ratios (ORs) for the association between patient characteristics and the likelihood of physicians recommending combination therapy (EGFR-TKI plus platinum/pemetrexed chemotherapy or EGFR-TKI plus bispecific antibody) versus EGFR-TKI monotherapy | Day of interview/survey completion(Day1) | o OR quantifies changes in the likelihood of physicians recommending combination therapy over monotherapy, depending on the presence or absence of specific patient characteristics (e.g., age, CNS metastases, high tumor burden). An OR \> 1 indicates an increased likelihood of recommending combination therapy for patients with the characteristic, while an OR \< 1 indicates a decreased likelihood. |
Countries
China
Contacts
CONTACTAstraZeneca Clinical Study Information Center
Outcome results
None listed